Morandi et al. [19] analysed the RET co-receptor ligand GDNF and its signalling pathway in a GDNF-response gene set and correlated it to a dataset of 81 ER positive breast cancer patients as well as 597 breast cancer samples from “The Cancer Genome Atlas” [32] Not only did they find a significant higher GDNF score in Luminal B breast cancer subtype in both data sets, but also a decreased distant metastasis free survival, relapse free survival and overall survival in this subtype [19]. The gene discussed is RET; the disease is breast cancer.